Surveillance of Carbapenem-resistant Klebsiella Pneumoniae: Tracking Molecular Epidemiology and Outcomes Through a Regional Network
Overview
Authors
Affiliations
Carbapenem resistance in Gram-negative bacteria is on the rise in the United States. A regional network was established to study microbiological and genetic determinants of clinical outcomes in hospitalized patients with carbapenem-resistant (CR) Klebsiella pneumoniae in a prospective, multicenter, observational study. To this end, predefined clinical characteristics and outcomes were recorded and K. pneumoniae isolates were analyzed for strain typing and resistance mechanism determination. In a 14-month period, 251 patients were included. While most of the patients were admitted from long-term care settings, 28% of them were admitted from home. Hospitalizations were prolonged and complicated. Nonsusceptibility to colistin and tigecycline occurred in isolates from 7 and 45% of the patients, respectively. Most of the CR K. pneumoniae isolates belonged to repetitive extragenic palindromic PCR (rep-PCR) types A and B (both sequence type 258) and carried either blaKPC-2 (48%) or blaKPC-3 (51%). One isolate tested positive for blaNDM-1, a sentinel discovery in this region. Important differences between strain types were noted; rep-PCR type B strains were associated with blaKPC-3 (odds ratio [OR], 294; 95% confidence interval [CI], 58 to 2,552; P < 0.001), gentamicin nonsusceptibility (OR, 24; 95% CI, 8.39 to 79.38; P < 0.001), amikacin susceptibility (OR, 11.0; 95% CI, 3.21 to 42.42; P < 0.001), tigecycline nonsusceptibility (OR, 5.34; 95% CI, 1.30 to 36.41; P = 0.018), a shorter length of stay (OR, 0.98; 95% CI, 0.95 to 1.00; P = 0.043), and admission from a skilled-nursing facility (OR, 3.09; 95% CI, 1.26 to 8.08; P = 0.013). Our analysis shows that (i) CR K. pneumoniae is seen primarily in the elderly long-term care population and that (ii) regional monitoring of CR K. pneumoniae reveals insights into molecular characteristics. This work highlights the crucial role of ongoing surveillance of carbapenem resistance determinants.
Saito S, Sakurai A, Matsumura Y, Uemura K, Hase R, Kato H JAC Antimicrob Resist. 2025; 7(2):dlaf027.
PMID: 40051884 PMC: 11882498. DOI: 10.1093/jacamr/dlaf027.
Sharma Y, Thompson C, Zinellu A, Shahi R, Horwood C, Mangoni A Clin Med (Lond). 2024; 25(1):100278.
PMID: 39672544 PMC: 11731571. DOI: 10.1016/j.clinme.2024.100278.
Baltas I, Patel T, Lima Soares A J Antimicrob Chemother. 2024; 80(1):59-67.
PMID: 39504496 PMC: 11695913. DOI: 10.1093/jac/dkae367.
Jacobs M, Good C, Abdelhamed A, Mack A, Bethel C, Marshall S Antimicrob Agents Chemother. 2024; 68(12):e0112724.
PMID: 39475259 PMC: 11619242. DOI: 10.1128/aac.01127-24.
A molecular analysis of meropenem-vaborbactam non-susceptible KPC-producing .
Yasmin M, Marshall S, Chen L, Rhoads D, Jacobs M, Rojas L Antimicrob Agents Chemother. 2024; 68(10):e0020824.
PMID: 39162528 PMC: 11459940. DOI: 10.1128/aac.00208-24.